GH Research PLC Cash Flow Conversion Efficiency
GH Research PLC cash flow conversion efficiency. Based on the latest financial reports, GH Research PLC (GHRS) has a cash flow conversion efficiency ratio of -0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.02 Million) by net assets ($359.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GH Research PLC (2019–2025)
Cash flow conversion efficiency of GH Research PLC from 2019 to 2025. This chart illustrates how GH Research PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for GH Research PLC for real-time trading data and today's change.
GH Research PLC Cash Flow Conversion Ratio Explained
GH Research PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GH Research PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GH Research PLC ranked by their cash flow conversion efficiency. Also see GH Research PLC stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Distribution Solutions Group Inc
NASDAQ:DSGR
|
0.059x |
|
Television Francaise 1 SA
PA:TFI
|
0.057x |
|
BW Energy Ltd
OL:BWE
|
0.315x |
|
MI Technovation Bhd
KLSE:5286
|
0.053x |
|
Gemdale Corp
SHG:600383
|
-0.002x |
|
Greattown Holdings Ltd A
SHG:600094
|
0.014x |
|
Shenzhen Kingdom SCI Tech Co Ltd
SHG:600446
|
0.005x |
|
VIVENDI UNSPON.ARD EO 55
F:VVUD
|
N/A |
Annual Cash Flow Conversion Efficiency for GH Research PLC (2019–2025)
The table below shows the annual cash flow conversion efficiency of GH Research PLC from 2019 to 2025. Review GH Research PLC (GHRS) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $279.70 Million | $-43.55 Million | -0.156x | +34.10% |
| 2024-12-31 | $178.95 Million | $-42.28 Million | -0.236x | -55.21% |
| 2023-12-31 | $218.97 Million | $-33.34 Million | -0.152x | -45.17% |
| 2022-12-31 | $249.82 Million | $-26.20 Million | -0.105x | -90.20% |
| 2021-12-31 | $277.18 Million | $-15.28 Million | -0.055x | +5.33% |
| 2020-12-31 | $5.67 Million | $-330.00K | -0.058x | +91.94% |
| 2019-12-31 | $400.00K | $-289.00K | -0.723x | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more